Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 3, 2008

View Archived Issues

Synergistic antimicrobial drug combinations may favor the development of resistance

Eupatilin induces apoptosis in colon cancer cell line

Novel compounds intended for treatment of obesity reported in recent patents

Tamsulosin-tolterodine ER combination improves ureteral stent-related urinary symptoms

Recent patents impart new oncolytic drugs

TRC-105 tolerated, active in ongoing phase I cancer study

Galapagos and CHDI sign new collaboration agreements in Huntington's disease

Osaka University patents compounds for treatment of periodontitis

Affitech acquires diabody technology from Pharmexa

Graffinity signs global multidrug discovery collaboration with AstraZeneca

Pharmexa and Kael enter into an agreement regarding GV-1001

New radiotherapeutic shows promising results in murine and primate melanoma models

Novel antisense oligonucleotide safe in preliminary data from phase I advanced cancer study

FDA approves Kringle's IND to initiate phase I trial of recombinant human HGF in ARF

FDA approves new indication for Hospira's Precedex in nonintubated patients

Biogen and Genentech to develop and commercialize GA-101 in the U.S.

Aastrom achieves milestone in U.S. phase IIb critical limb ischemia trial

Anadys commences dosing of ANA-773 in hepatitis C patients

Bayhill and Juvenile Diabetes Research Foundation enter research collaboration

RAPID 1 study shows Cimzia rapidly reduces symptoms and progression of RA

Spectrum files sNDA with FDA for Fusilev in colorectal cancer

Polyphor signs exclusive agreement with Allergan for PEM inhibitors in ophthalmology

FDA approves fesoterodine for overactive bladder

Apriso approved by FDA for ulcerative colitis

Savient submits BLA to FDA for pegloticase

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 7, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 6, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...